Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors | OncotargetAriunzaya Bat-Erdene, Hirokazu Miki, Asuko Oda, Shingen Nakamura, Jumpei Teramachi, Ryota Amachi, Hirofumi Tenshin, Masahiro Hiasa, Masami Iwasa, Takeshi Harada, Shiro Fujii, Kimiko Sogabe, Kumiko Kagawa, Sumiko Yoshida, Itsuro Endo, Kenichi Aihara and Masahiro Abe _Oncotarget. 2016; 7:79064-79075. https://doi.org/10.18632/oncotarget.12594Metrics: PDF 872 views	| HTML 1244 views	| ?Ariunzaya Bat-Erdene1, Hirokazu Miki2, Asuko Oda1, Shingen Nakamura1, Jumpei Teramachi1,4, Ryota Amachi1,3, Hirofumi Tenshin1,3, Masahiro Hiasa1,3, Masami Iwasa1, Takeshi Harada1, Shiro Fujii1, Kimiko Sogabe1, Kumiko Kagawa1, Sumiko Yoshida1, Itsuro Endo1, Kenichi Aihara1, Masahiro Abe11Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School of Medicine, Tokushima, Japan2Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan3Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Oral Sciences, Tokushima, Japan4Department of Histology and Oral Histology, Tokushima University Graduate School of Oral Sciences, Tokushima, JapanMasahiro Abe, email: masabe@tokushima-u.ac.jpKeywords: multiple myeloma, panobinostat, proteasome inhibitors, caspase-8, Sp1Received: July 16, 2016 Accepted: September 29, 2016 Published: October 12, 2016PII: 12594
